uniQure (QURE) Income from Continuing Operations (2016 - 2026)
uniQure (QURE) posted quarterly Income from Continuing Operations of 81059000.0 for Q2 2026, down 114.9% year-over-year from 543936029.35 in Q2 2025, and down 51.41% quarter-over-quarter from 53535000.0 in Q1 2026.
Powered by 
Analysis
uniQure (QURE) Income from Continuing Operations (2016 - 2026) Analysis & Trends
uniQure's Income from Continuing Operations history runs 11 years deep, the most recent figure standing at 81059000.0 for Q2 2026.
- In Q2 2026, Income from Continuing Operations fell 114.9% year-over-year to 81059000.0; the TTM figure through Jun 2026 stood at 196696000.0 (down 45.16% YoY), while the FY2025 annual figure was 143458000.0, up 18.47% from the prior year.
- Income from Continuing Operations for Q2 2026 stood at 81059000.0, down from 53535000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 38428000.0 in Q4 2022, with the low at 89571000.0 in Q3 2023.
- The 5-year median for Income from Continuing Operations is 47267500.0 (2022), against an average of 43152944.44.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations plunged 223.65% in 2024, then soared 290.89% in 2025.
- uniQure's Income from Continuing Operations stood at 38428000.0 in 2022, then sank by 79.68% to 7807000.0 in 2023, then slumped by 223.65% to 9653000.0 in 2024, then jumped by 290.89% to 18427000.0 in 2025, then sank by 539.89% to 81059000.0 in 2026.
- Business Quant data shows QURE's Income from Continuing Operations at 81059000.0 in Q2 2026, 53535000.0 in Q1 2026, and 18427000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn | -81.06 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -81.06 Mn |
| Mar 31, 2026 | -53.54 Mn |
| Dec 31, 2025 | 18.43 Mn |
| Sep 30, 2025 | -80.53 Mn |
| Jun 30, 2025 | -37.72 Mn |
| Mar 31, 2025 | -43.64 Mn |
| Dec 31, 2024 | -9.65 Mn |
| Sep 30, 2024 | -44.50 Mn |
| Jun 30, 2024 | -56.30 Mn |
| Mar 31, 2024 | -65.62 Mn |
| Dec 31, 2023 | 7.81 Mn |
| Sep 30, 2023 | -89.57 Mn |
| Jun 30, 2023 | -68.47 Mn |
| Mar 31, 2023 | -77.23 Mn |
| Dec 31, 2022 | 38.43 Mn |
| Sep 30, 2022 | -47.86 Mn |
| Jun 30, 2022 | -39.06 Mn |
| Mar 31, 2022 | -46.68 Mn |
| Dec 31, 2021 | -71.78 Mn |
| Sep 30, 2021 | -36.53 Mn |